What the research found

Researchers identified a cellular pathway involving CDK4/6 proteins that controls how senescent cells (permanently non-dividing cells that accumulate with age and after chemotherapy) trigger inflammatory signals. Using a CDK4/6 inhibitor called abemaciclib, they showed they could suppress this inflammation in senescent cells both in laboratory cultures and in living mice. The mechanism involves CDK4/6 proteins interacting with two other molecular regulators: RARα and NF-κB, which together drive the pro-inflammatory secretory profile of senescent cells.

In mice that had undergone chemotherapy, abemaciclib treatment improved physical function and reduced the ability of chemotherapy-induced senescent cells to promote tumour-related processes. The researchers also tested this approach in aged mice without prior chemotherapy, where the drug and an RARα-blocking compound both reduced systemic inflammatory markers and improved physical performance measures.

Why it matters for you

Senescent cell accumulation is thought to be a driver of age-related dysfunction — the "tired" feeling, reduced recovery, impaired physical performance that MyKine users often track over time. If senescent cells are part of your ageing phenotype, this research suggests that temporarily blocking CDK4/6 might dampen their inflammatory output without necessarily clearing them entirely.

For those who've undergone chemotherapy, lingering senescent cells can contribute to cancer-related fatigue and functional decline beyond the acute treatment phase. This work hints that a time-limited CDK4/6 inhibitor course could mitigate those longer-term effects. For biomarker trackers, this points toward NF-κB-driven inflammatory markers (like systemic IL-6, TNF-α, or CRP) as potential readouts of senescent cell burden and intervention response.

That said, this is mechanistic work in animals. Whether the doses, timing, and duration of CDK4/6 inhibition needed in humans would be practical or safe alongside your other protocols—peptides, TRT, training stress—remains untested.

Caveats

• Preclinical only. Studies in cell cultures and mice do not directly translate to human efficacy or safety.
• Short-term intervention. The research examined transient CDK4/6 blockade, not chronic use; human tolerability and long-term effects are unknown.
• Abemaciclib is already approved for breast cancer but has known side effects; repurposing for healthy ageing would require a different risk–benefit analysis.
• No direct human biomarker validation. The inflammatory markers measured are mouse-specific; human equivalents and their responsiveness are assumed, not proven.
• Senescent cell burden not directly measured. Physical function improved, but direct evidence that senescent cells decreased is inferred from mechanism, not directly quantified.